ICU

+ Watchlist + Portfolio

SeaStar Medical Holding Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.27
52-Week Range: $2.07 – $12.50
Market Cap: $14.72M
P/E (TTM): —
EPS (TTM): -1.89
Dividend Yield: —

Advanced Metrics

Price/Book: 1.23
PEG Ratio: —
Return on Equity: -356.87%
Return on Assets: -102.67%
Gross Margin: 92.64%
Operating Margin: -616.42%
Profit Margin: 0.00%
Current Ratio: 1.89
Debt/Equity: 0.03
Total Debt: $134.00K
Free Cash Flow: $-9.14M
Revenue Growth: 82.00%
Earnings Growth: —
Enterprise Value: $7.59M

ICU Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$135.00K	$1.23M
Cost of Revenue	—	$0.00	$0.00	$53.00K
Gross Profit	—	$0.00	$135.00K	$1.18M
Research & Development	$2.50M	$5.97M	$9.11M	$7.52M
Selling, General & Admin	$6.92M	$8.24M	$8.87M	$5.84M
Operating Expenses	$11.61M	$14.21M	$17.98M	$13.36M
Operating Income	-$11.61M	-$14.21M	-$17.84M	-$12.18M
EBITDA	-$11.56M	-$25.15M	-$24.58M	-$12.12M
Pretax Income	-$12.19M	-$26.23M	-$24.83M	-$12.15M
Income Tax	$1.00K	$0.00	$3.00K	$3.00K
Net Income	-$12.19M	-$26.23M	-$24.83M	-$12.15M
Diluted EPS	-700.00	-302.60	-66.30	-5.86
Diluted Shares	32845	86681	374355	2.07M

ICU Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$47.00K	$176.00K	$1.82M	$11.98M
Receivables	$12.00K	$0.00	$112.00K	$237.00K
Inventory	—	—	$0.00	$66.00K
Current Assets	$1.52M	$2.31M	$3.77M	$13.58M
Total Assets	$3.04M	$3.51M	$4.66M	$14.16M
Current Liabilities	$16.15M	$13.05M	$6.84M	$3.74M
Long-Term Debt	$7.65M	$4.34M	—	—
Total Debt	$8.83M	$9.08M	$574.00K	$525.00K
Total Liabilities	$23.80M	$17.38M	$6.84M	$3.74M
Retained Earnings	-$88.50M	-$114.73M	-$139.56M	-$151.71M
Shareholders' Equity	-$20.76M	-$13.87M	-$2.18M	$10.42M
Working Capital	-$14.63M	-$10.74M	-$3.08M	$9.84M
Net Debt	$8.78M	$8.90M	—	—

ICU Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$7.79M	-$10.29M	-$16.01M	-$13.60M
Free Cash Flow	-$7.79M	-$10.29M	-$16.01M	-$13.60M
Stock-Based Compensation	$1.31M	$1.93M	$887.00K	$624.00K
Financing Cash Flow	$7.33M	$10.41M	$17.65M	$23.76M
Net Change in Cash	-$463.00K	$129.00K	$1.64M	$10.16M

ICU Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$293.00K	$338.00K	$183.00K	$420.00K	$495.00K
Cost of Revenue	$0.00	$27.00K	$14.00K	$12.00K	$46.00K
Gross Profit	$293.00K	$311.00K	$169.00K	$408.00K	$449.00K
Research & Development	$2.43M	$1.04M	$1.85M	$2.20M	$2.34M
Selling, General & Admin	$1.68M	$1.03M	$1.90M	$1.22M	$1.71M
Operating Expenses	$4.12M	$2.07M	$3.75M	$3.42M	$4.05M
Operating Income	-$3.82M	-$1.76M	-$3.58M	-$3.02M	-$3.60M
EBITDA	-$3.76M	-$1.99M	-$3.47M	-$2.89M	-$3.51M
Pretax Income	-$3.77M	-$2.00M	-$3.47M	-$2.90M	-$3.52M
Income Tax	$3.00K	$0.00	$0.00	$0.00	$3.00K
Net Income	-$3.77M	-$2.00M	-$3.47M	-$2.90M	-$3.52M
Diluted EPS	-4.40	-1.80	-1.30	-0.80	-0.90
Diluted Shares	861793	1.13M	2.64M	3.62M	3.92M

ICU Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.30M	$6.30M	$13.76M	$11.98M	$9.35M
Receivables	$110.00K	$217.00K	$221.00K	$237.00K	$179.00K
Inventory	$44.00K	$77.00K	$83.00K	$66.00K	$57.00K
Current Assets	$6.78M	$7.65M	$14.87M	$13.58M	$10.76M
Total Assets	$7.60M	$8.38M	$15.53M	$14.16M	$11.26M
Current Liabilities	$7.03M	$5.04M	$4.07M	$3.74M	$3.95M
Total Debt	$363.00K	—	—	$525.00K	$331.00K
Total Liabilities	$7.03M	$5.04M	$4.07M	$3.74M	$3.95M
Retained Earnings	-$143.34M	-$145.34M	-$148.81M	-$151.71M	-$155.24M
Shareholders' Equity	$565.00K	$3.34M	$11.46M	$10.42M	$7.32M
Working Capital	-$248.00K	$2.60M	$10.81M	$9.84M	$6.82M

ICU Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.65M	-$3.01M	-$3.84M	-$4.09M	-$2.76M
Free Cash Flow	-$2.65M	-$3.01M	-$3.84M	-$4.09M	-$2.76M
Stock-Based Compensation	$167.00K	$97.00K	$290.00K	$70.00K	$91.00K
Financing Cash Flow	$6.13M	$4.01M	$11.30M	$2.31M	$129.00K
Net Change in Cash	$3.48M	$1.01M	$7.46M	-$1.78M	-$2.63M

Market Snapshot

About

SeaStar Medical Holding Corporation is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation in acute and chronic conditions. The company's lead product, the Selective Cytopheretic Device (SCD), is designed to remove activated neutrophils from blood during extracorporeal therapy to modulate inflammation. SeaStar Medical is initially targeting applications in acute kidney injury requiring dialysis and other critical care conditions characterized by excessive inflammation. The company's technology platform aims to address unmet medical needs in life-threatening conditions driven by dysregulated immune responses.